EGFR inhibitors have been previously reported to down-regulate PD-L1 expression in lung cancer cell lines carrying sensitizing EGFR mutations, suggesting that they may potentially function as immune-modulators in addition to their direct cytotoxic effects on tumor cells [21,22]. The gene discussed is CD274; the disease is lung carcinoma.